Codexis, Inc. (CDXS)
$1.01
-0.04 (-3.81%)Delayed quote.
Price history
Daily close- Start
- $1.59
- Latest close
- $1.01
- Period change
- -36.48%
- Period low
- $0.96
- Period high
- $2.85
Key metrics
- Market cap
- $110.69M
- Volume
- 2.07M
- Average volume
- 1.11M
- 52-week range
- $0.90 – $2.98
- Beta
- 2.39
- Last dividend
- —
- EPS (TTM)
- -$0.20
- P/E ratio
- -3.26
- Revenue (TTM)
- $88.34M
- Net income (TTM)
- -$19.24M
- Total assets
- $144.22M
- Total debt
- $72.27M
- Cash and equivalents
- $29.21M
Key financials (trailing twelve months).
Company profile
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- CEO
- Alison Moore
- Employees
- 146
- Headquarters
- Redwood City, CA, US
- IPO date
- 2010-04-22
- Website
- https://www.codexis.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Revenue | $70.39M | $59.34M | $70.14M |
| Gross profit | $61.05M | $43.06M | $57.33M |
| Operating income | -$38.33M | -$58.52M | -$68.07M |
| EBITDA | -$33.87M | -$53.41M | -$44.88M |
| Net income | -$43.97M | -$65.28M | -$76.24M |
| Diluted EPS | -$0.50 | -$0.89 | -$1.12 |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $50.79M | $19.26M | $65.12M |
| Total assets | $147.80M | $149.01M | $136.56M |
| Total liabilities | $97.27M | $82.08M | $49.95M |
| Total debt | $73.21M | $59.90M | $16.02M |
| Shareholders’ equity | $50.53M | $66.93M | $86.61M |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$19.38M | -$49.41M | -$52.64M |
| Capital expenditure | -$4.47M | -$4.30M | -$4.42M |
| Free cash flow | -$23.85M | -$53.72M | -$57.06M |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $19.26M | $14.91M | $15.25M | $38.91M | $8.60M | $15.33M |
| Gross profit | $15.25M | $11.40M | $11.94M | $35.55M | $6.14M | $11.93M |
| Operating income | -$7.44M | -$11.23M | -$8.04M | $13.96M | -$18.95M | -$12.86M |
| EBITDA | -$5.64M | -$9.84M | -$6.45M | $11.84M | -$16.22M | -$11.26M |
| Net income | -$8.13M | -$12.01M | -$8.70M | $9.60M | -$19.61M | -$13.27M |
| Diluted EPS | -$0.08 | -$0.13 | -$0.10 | $0.11 | -$0.22 | -$0.16 |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $29.21M | $27.17M | $37.00M | $50.79M | $25.84M | $26.76M |
| Total assets | $144.22M | $120.06M | $129.37M | $147.80M | $123.96M | $138.25M |
| Total liabilities | $92.98M | $87.10M | $86.14M | $97.27M | $85.42M | $82.61M |
| Total debt | $72.27M | $72.59M | $72.90M | $73.21M | $68.62M | $68.98M |
| Shareholders’ equity | $51.24M | $32.96M | $43.23M | $50.53M | $38.54M | $55.63M |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.77M | -$9.64M | -$13.15M | $20.09M | -$7.70M | -$17.97M |
| Capital expenditure | -$74.0K | -$898.0K | -$176.0K | -$520.0K | -$182.0K | -$2.51M |
| Free cash flow | -$7.84M | -$10.54M | -$13.33M | $19.57M | -$7.88M | -$20.48M |